Andrea Pfeifer Sells 10,000 Shares of AC Immune (NASDAQ:ACIU) Stock

AC Immune (NASDAQ:ACIU) CEO Andrea Pfeifer sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $2.79, for a total transaction of $27,900.00. Following the completion of the sale, the chief executive officer directly owned 3,820,288 shares of the company’s stock, valued at approximately $10,658,603.52. This represents a 0.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AC Immune Price Performance

ACIU opened at $2.82 on Wednesday. The company has a fifty day moving average price of $2.95 and a two-hundred day moving average price of $3.07. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.87. AC Immune has a 52 week low of $1.60 and a 52 week high of $4.00. The firm has a market capitalization of $286.99 million, a PE ratio of -3.44 and a beta of 1.65.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. The company had revenue of $1.40 million during the quarter, compared to analyst estimates of $0.33 million. As a group, analysts anticipate that AC Immune will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. EFG International AG bought a new position in AC Immune in the 4th quarter valued at about $41,000. Private Advisor Group LLC acquired a new position in shares of AC Immune during the 3rd quarter worth approximately $48,000. Sei Investments Co. acquired a new position in shares of AC Immune during the 2nd quarter worth approximately $51,000. Goldman Sachs Group Inc. grew its position in shares of AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after purchasing an additional 5,920 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of AC Immune in the third quarter valued at approximately $63,000. 51.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

ACIU has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings downgraded shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. Jefferies Financial Group restated a “buy” rating and set a $7.00 price objective on shares of AC Immune in a research note on Friday, March 13th. Finally, BTIG Research restated a “buy” rating and set a $8.00 price objective on shares of AC Immune in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $7.50.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.